M&A Deal Summary

Shire Acquires Shire Regenerative Medicine

On June 28, 2011, Shire acquired life science company Shire Regenerative Medicine from Safeguard for 750M USD

Acquisition Highlights
  • This is Shire’s 3rd transaction in the Life Science sector.
  • This is Shire’s 5th largest (disclosed) transaction.
  • This is Shire’s 2nd transaction in the United States.
  • This is Shire’s 1st transaction in Connecticut.

M&A Deal Summary
Date 2011-06-28
Target Shire Regenerative Medicine
Sector Life Science
Buyer(s) Shire
Sellers(s) Safeguard
Deal Type Add-on Acquisition
Deal Value 750M USD
Advisor(s) BofA Securities (Financial)

Target

Shire Regenerative Medicine

Westport, Connecticut, United States
Shire Regenerative Medicine, Inc. is a regenerative medicine company that develops, manufactures and commercializes living cell-based therapies for regenerative medicine.

Search 201,771 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Shire

Dublin, Ireland
Category Company
Founded 1986
Sector Life Science
Employees5,548
Revenue 6.4B USD (2015)
DESCRIPTION

Shire plc is a global specialty biopharmaceutical company. Shire plc strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

DEAL STATS #
Overall 3 of 16
Sector (Life Science) 3 of 15
Type (Add-on Acquisition) 2 of 14
State (Connecticut) 1 of 1
Country (United States) 2 of 13
Year (2011) 1 of 1
Size (of disclosed) 5 of 12
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-04-28 Transkaryotic Therapies

Cambridge, Massachusetts, United States

Transkaryotic Therapies, Inc. (TKT) is a biopharmaceutical company dedicated to the development and commercialization of products based on its three proprietary development platforms: Gene-Activated proteins, Niche Protein products and Gene Therapy.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-03-15 FerroKin BioSciences

San Carlos, California, United States

Ferrokin Biosciences develops and markets medical devices such as Iron Chelator for the treatment of iron-overload in patients.

Buy $325M

Seller(S) 1

SELLER

Safeguard

Radnor, Pennsylvania, United States
Category Company
Sector Financial Services
Employees30
Revenue 6M USD (2023)
DESCRIPTION

Safeguard is a provider of capital and operational expertise to emerging and growth-stage healthcare and technology enterprises that are developing innovative products and services.

DEAL STATS #
Overall 4 of 9
Sector (Life Science) 2 of 3
Type (Add-on Acquisition) 2 of 3
State (Connecticut) 1 of 1
Country (United States) 4 of 9
Year (2011) 2 of 2
Size (of disclosed) 1 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-06-22 Portico Systems

Blue Bell, Pennsylvania, United States

Portico Systems, Inc. offers health plans enterprise-class software solutions built exclusively to support end-to-end Provider Network Operations. Since 1997, Portico™ Systems has been enabling payers to streamline their provider business processes. Portico™ Systems leverages a unique blend of healthcare operations experience, payer/provider relationship expertise and technology skills to build holistic solutions.

Sell $90M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-01-03 Crescendo Bioscience

South San Francisco, California, United States

Crescendo Bioscience, Inc. is a molecular diagnostics company dedicated to developing and commercializing quantitative blood tests for rheumatoid arthritis (RA) and other autoimmune diseases.

Buy -
Mergr

Product

Company

Legal